Person: Xu, George
Email Address
AA Acceptance Date
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
First Name
Name
Search Results
Publication PhIP-Seq Characterization of Autoantibodies From Patients With Multiple Sclerosis, Type 1 Diabetes and Rheumatoid Arthritis
(Elsevier BV, 2013-06) Larman, H. Benjamin; Laserson, Uri; Querol, Luis; Verhaeghen, Katrijn; Solimini, Nicole L.; Xu, George; Klarenbeek, Paul L.; Church, George; Hafler, David A.; Plenge, Robert M.; Nigrovic, Peter; De Jager, Philip; Weets, Ilse; Martens, Geert A.; O'Connor, Kevin C.; Elledge, StephenAutoimmune disease results from a loss of tolerance to self-antigens in genetically susceptible individuals. Completely understanding this process requires that targeted antigens be identified, and so a number of techniques have been developed to determine immune receptor specificities. We previously reported the construction of a phage-displayed synthetic human peptidome and a proof-of-principle analysis of antibodies from three patients with neurological autoimmunity. Here we present data from a large-scale screen of 298 independent antibody repertoires, including those from 73 healthy sera, using phage immunoprecipitation sequencing. The resulting database of peptide-antibody interactions characterizes each individual’s unique autoantibody fingerprint, and includes specificities found to occur frequently in the general population as well as those associated with disease. Screening type 1 diabetes (T1D) patients revealed a prematurely polyautoreactive phenotype compared with their matched controls. A collection of cerebrospinal fluids and sera from 63 multiple sclerosis patients uncovered novel, as well as previously reported antibody-peptide interactions. Finally, a screen of synovial fluids and sera from 64 rheumatoid arthritis patients revealed novel disease-associated antibody specificities that were independent of seropositivity status. This work demonstrates the utility of performing PhIP-Seq screens on large numbers of individuals and is another step toward defining the full complement of autoimmunoreactivities in health and disease.